← Back to Screener
Coya Therapeutics, Inc. Common Stock (COYA)
Price$4.99
Favorite Metrics
Price vs S&P 500 (26W)-30.00%
Price vs S&P 500 (4W)4.05%
Market Capitalization$112.13M
All Metrics
Book Value / Share (Quarterly)$2.06
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.51
Price vs S&P 500 (YTD)-21.72%
Net Profit Margin (TTM)-267.14%
EPS (TTM)$-1.27
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-1.27
EPS (Annual)$-1.27
ROI (Annual)-49.33%
Cash / Share (Quarterly)$2.24
Revenue Growth QoQ (YoY)202976.92%
ROA (Last FY)-42.49%
Revenue Growth TTM (YoY)123.57%
EBITD / Share (TTM)$-1.27
ROE (5Y Avg)-50.50%
Operating Margin (TTM)-283.87%
Cash Flow / Share (Annual)$-0.51
P/B Ratio2.61x
P/B Ratio (Quarterly)2.82x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)8.22x
Net Interest Coverage (TTM)-17.25x
ROA (TTM)-55.19%
EPS Incl Extra (Annual)$-1.27
Current Ratio (Annual)8.50x
Quick Ratio (Quarterly)7.97x
3-Month Avg Trading Volume0.20M
52-Week Price Return-8.43%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.01
P/S Ratio (Annual)14.11x
Asset Turnover (Annual)0.16x
52-Week High$7.75
EPS Excl Extra (Annual)$-1.27
26-Week Price Return-21.25%
Quick Ratio (Annual)7.97x
13-Week Price Return3.02%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.50x
Enterprise Value$65.303
Asset Turnover (TTM)0.21x
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-267.10%
Cash / Share (Annual)$2.24
3-Month Return Std Dev63.65%
Net Income / Employee (TTM)$-3
ROE (Last FY)-49.33%
EPS Basic Excl Extra (Annual)$-1.27
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.27
ROI (TTM)-64.33%
P/S Ratio (TTM)14.11x
Revenue / Share (Annual)$0.47
Tangible BV / Share (Annual)$-0.84
Price vs S&P 500 (52W)-43.52%
Year-to-Date Return-17.59%
5-Day Price Return7.42%
EPS Normalized (Annual)$-1.27
ROA (5Y Avg)-68.64%
Net Profit Margin (Annual)-267.14%
Month-to-Date Return21.32%
Cash Flow / Share (TTM)$-1.22
EBITD / Share (Annual)$-1.27
Operating Margin (Annual)-283.87%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.50%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.27
P/TBV (Quarterly)5.01x
P/B Ratio (Annual)2.82x
Pretax Margin (TTM)-267.10%
Book Value / Share (Annual)$2.06
Price vs S&P 500 (13W)0.15%
Beta0.78x
Revenue / Share (TTM)$0.47
ROE (TTM)-64.33%
52-Week Low$3.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.15
4.15
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
COYACoya Therapeutics, Inc. Common Stock | 14.11x | 123.57% | — | — | $4.99 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Coya Therapeutics is a clinical-stage biotech company developing regulatory T cell therapies for neurodegenerative, autoimmune, and metabolic diseases. The company's proprietary multi-modality platform modulates Treg function to address multiple disease indications.